Back to directory
We are building an AI powered eye disease diagnostic system
Houston
HealthcareMedical Devices
See something off about this company?
We are building an AI powered eye disease diagnostic system
At Ai-Ris, where we are disrupting the diagnostics space with a ML/AI headset for eye exams in the primary care setting. We are going after the leading cause of preventable blindness - diabetic vision loss (34M pts/year) and our technology has applications to detect Alzheimer's, Cardiac arrests etc., early. It is estimated that this form of vision loss can affect 34million Americans each year with its economic burden amounting to 21 billion dollars. Our technology will radically bring this price down by increasing access to eye exams by 10-fold. Thus far, we've been NSF SBIR funded, have clinical partnerships with Harvard and UT San Antonio, are published in Nature and Cell, have signed letter of intents, and we are currently raising our first round.
See something off about this company?
Uthej Vattipalli
founder
Vision Loss due to diabetes is a huge problem affecting up to 34 million people each year in U.S. and over 200million globally. Early detection is key to prevention, but due to lack of easy access to retinal exams, most people go undiagnosed and suffer from vision loss. After going through the NSF National ICORPS program and conducting over 300 customer interviews, we decided our target market as primary care clinics located in the U.S. Specifically, clinics that participate in “Medicare Advantage” or other quality-based care programs that receive insurance reimbursement corresponding to their ability to meet specific quality-based measures, which includes the percentage of diabetic patients receiving their yearly retinal exam. However, physicians have no way to ensure that their patients see a specialist for their eye exam. With the rise of such quality-based care programs, we are noticing a strong trend for PCPs to offer robust services.
Thus far, we've been NSF SBIR funded, have clinical partnerships with Harvard and UT San Antonio, are published in Nature and Cell, have signed letter of intents, and we are currently raising our first round.